EarlyNarratives
Today
MethodologyPricing
Get free brief
Get free brief
Storylines

Storylines

Track narrative continuity separately from authoritative updates and early community radar.

How to use: choose continuity or verified updates → open one card → inspect its current sources and evidence status.

Selection window 24hSelection window for ranking; freshness is shown by the Updated badge.Current detail open
Current storylines stay open here with summary, metadata, source links, continuity context, and what to keep watching next. Upgrade for archive, compare-over-time, alerts, exports, and workflow.This Week’s Brief
Today’s BriefSignalsThis Week’s Brief
Featured nowEditorial emphasis
FDA makes acting CDER and CBER chiefs permanent
Featured highlights editorial emphasis only. Current source links stay open across the live brief.
The FDA leadership update is framed as a continuity story: Mikhail and Davis were named permanent leaders of CBER and CDER, respectively, after a period of turnover in the agency’s senior ranks.
  • FDA CDER leadership bios
    fda.gov
  • BioPharma Dive
    biopharmadive.com
  • Pharmaphorum
    pharmaphorum.com
Open current signalGet the brief free by email
Storylines dashboard
UpdatingNext sync pending

Sorted by momentum. Use the chevron to expand a card. Use the action button for the full drawer.

No investment advice. Research signals and sources only. EarlyNarratives provides informational signals derived from public sources. It does not provide financial, legal, or tax advice.

Category
Ongoing narratives are separated from authoritative updates and update digests. One issuer is not cross-source confirmation.
Filter matches title, tags, and tickers.
From This Week's Brief

Editorial weekly synthesis. Use the tracker below for continuity between issues.

No weekly storylines yet.

Continuity tracker

Track what changed, what held, and what to watch next across recent runs. Sorted by momentum.

Storyline

Guide-RNA design as a precision lever for genome editing

Two bioRxiv preprints examine guide-RNA design strategies for improving editing selectivity. One studies modified crRNAs for targeting point mutations in human mitochondrial DNA, while the other assesses truncated gRNAs for effects on base-editing efficiency, bystander activity, and large deletions.

Updated 34h agoActive span 12h
Limited history
Details
Evidence: 1 primary
Limited historyLow evidence
Why now
  • Two related preprints were posted in the current briefing window.
  • Both examine guide-RNA design without changing the core editing platforms.
Open detail
Upgrade for archive, alerts, and workflow

Free gives current signals and storylines with source links. Pro adds archive, alerts, watchlists, exports, and workflow tools. Business adds Feed API and team usage.

Start free trialAlready subscribed? Sign in
Pro adds archive, search, alerts, watchlists, exports, and individual workflow tools. Cancel anytime.